238 related articles for article (PubMed ID: 23166343)
1. Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac Outcomes.
Lipshultz SE; Miller TL; Lipsitz SR; Neuberg DS; Dahlberg SE; Colan SD; Silverman LB; Henkel JM; Franco VI; Cushman LL; Asselin BL; Clavell LA; Athale U; Michon B; Laverdière C; Schorin MA; Larsen E; Usmani N; Sallan SE;
Pediatrics; 2012 Dec; 130(6):1003-11. PubMed ID: 23166343
[TBL] [Abstract][Full Text] [Related]
2. Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol.
Lipshultz SE; Giantris AL; Lipsitz SR; Kimball Dalton V; Asselin BL; Barr RD; Clavell LA; Hurwitz CA; Moghrabi A; Samson Y; Schorin MA; Gelber RD; Sallan SE; Colan SD
J Clin Oncol; 2002 Mar; 20(6):1677-82. PubMed ID: 11896119
[TBL] [Abstract][Full Text] [Related]
3. Long-term complications of therapeutic exposures in childhood: lessons learned from childhood cancer survivors.
Bhatia S
Pediatrics; 2012 Dec; 130(6):1141-3. PubMed ID: 23166341
[No Abstract] [Full Text] [Related]
4. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial.
Lipshultz SE; Scully RE; Lipsitz SR; Sallan SE; Silverman LB; Miller TL; Barry EV; Asselin BL; Athale U; Clavell LA; Larsen E; Moghrabi A; Samson Y; Michon B; Schorin MA; Cohen HJ; Neuberg DS; Orav EJ; Colan SD
Lancet Oncol; 2010 Oct; 11(10):950-61. PubMed ID: 20850381
[TBL] [Abstract][Full Text] [Related]
5. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes.
Lipshultz SE; Miller TL; Scully RE; Lipsitz SR; Rifai N; Silverman LB; Colan SD; Neuberg DS; Dahlberg SE; Henkel JM; Asselin BL; Athale UH; Clavell LA; Laverdière C; Michon B; Schorin MA; Sallan SE
J Clin Oncol; 2012 Apr; 30(10):1042-9. PubMed ID: 22370326
[TBL] [Abstract][Full Text] [Related]
6. Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children's Oncology Group Randomized Trial Pediatric Oncology Group 9404.
Asselin BL; Devidas M; Chen L; Franco VI; Pullen J; Borowitz MJ; Hutchison RE; Ravindranath Y; Armenian SH; Camitta BM; Lipshultz SE
J Clin Oncol; 2016 Mar; 34(8):854-62. PubMed ID: 26700126
[TBL] [Abstract][Full Text] [Related]
7. Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review.
Bryant J; Picot J; Levitt G; Sullivan I; Baxter L; Clegg A
Health Technol Assess; 2007 Jul; 11(27):iii, ix-x, 1-84. PubMed ID: 17610809
[TBL] [Abstract][Full Text] [Related]
8. Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia.
Lipshultz SE; Lipsitz SR; Kutok JL; Miller TL; Colan SD; Neuberg DS; Stevenson KE; Fleming MD; Sallan SE; Franco VI; Henkel JM; Asselin BL; Athale UH; Clavell LA; Michon B; Laverdiere C; Larsen E; Kelly KM; Silverman LB
Cancer; 2013 Oct; 119(19):3555-62. PubMed ID: 23861158
[TBL] [Abstract][Full Text] [Related]
9. Does anthracycline administration by infusion in children affect late cardiotoxicity?
Levitt GA; Dorup I; Sorensen K; Sullivan I
Br J Haematol; 2004 Feb; 124(4):463-8. PubMed ID: 14984495
[TBL] [Abstract][Full Text] [Related]
10. Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer.
Lipshultz SE; Lipsitz SR; Mone SM; Goorin AM; Sallan SE; Sanders SP; Orav EJ; Gelber RD; Colan SD
N Engl J Med; 1995 Jun; 332(26):1738-43. PubMed ID: 7760889
[TBL] [Abstract][Full Text] [Related]
11. Anthracycline dose in childhood acute lymphoblastic leukemia: issues of early survival versus late cardiotoxicity.
Sorensen K; Levitt G; Bull C; Chessells J; Sullivan I
J Clin Oncol; 1997 Jan; 15(1):61-8. PubMed ID: 8996125
[TBL] [Abstract][Full Text] [Related]
12. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia.
Lipshultz SE; Rifai N; Dalton VM; Levy DE; Silverman LB; Lipsitz SR; Colan SD; Asselin BL; Barr RD; Clavell LA; Hurwitz CA; Moghrabi A; Samson Y; Schorin MA; Gelber RD; Sallan SE
N Engl J Med; 2004 Jul; 351(2):145-53. PubMed ID: 15247354
[TBL] [Abstract][Full Text] [Related]
13. Low anthracyclines doses-induced cardiotoxicity in acute lymphoblastic leukemia long-term female survivors.
Amigoni M; Giannattasio C; Fraschini D; Galbiati M; Capra AC; Madotto F; Cesana F; Jankovic M; Masera G; Mancia G
Pediatr Blood Cancer; 2010 Dec; 55(7):1343-7. PubMed ID: 20589666
[TBL] [Abstract][Full Text] [Related]
14. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia.
Lipshultz SE; Lipsitz SR; Sallan SE; Dalton VM; Mone SM; Gelber RD; Colan SD
J Clin Oncol; 2005 Apr; 23(12):2629-36. PubMed ID: 15837978
[TBL] [Abstract][Full Text] [Related]
15. Dexrazoxane and Long-Term Heart Function in Survivors of Childhood Cancer.
Chow EJ; Aggarwal S; Doody DR; Aplenc R; Armenian SH; Baker KS; Bhatia S; Blythe N; Colan SD; Constine LS; Freyer DR; Kopp LM; Laverdière C; Leisenring WM; Sasaki N; Vrooman LM; Asselin BL; Schwartz CL; Lipshultz SE
J Clin Oncol; 2023 Apr; 41(12):2248-2257. PubMed ID: 36669148
[TBL] [Abstract][Full Text] [Related]
16. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
[TBL] [Abstract][Full Text] [Related]
17. Protective role of black seed oil in doxorubicin-induced cardiac toxicity in children with acute lymphoblastic leukemia.
Hagag AA; Badraia IM; El-Shehaby WA; Mabrouk MM
J Oncol Pharm Pract; 2020 Sep; 26(6):1397-1406. PubMed ID: 31964219
[TBL] [Abstract][Full Text] [Related]
18. Daunorubicin-induced cell kill with 1-hour versus 24-hour infusions: a randomized comparison in children with newly diagnosed acute lymphoblastic leukemia.
Escherich G; Göbel U; Jorch N; Spaar HJ; Janka-Schaub GE
Klin Padiatr; 2007; 219(3):134-8. PubMed ID: 17525906
[TBL] [Abstract][Full Text] [Related]
19. Protective Role of Silymarin in Early Doxorubicin-induced Cardiac Dysfunction in Children with Acute Lymphoblastic Leukemia.
Hagag AA; El Shehaby WA; El-Abasy AI; Mabrouk MM
Infect Disord Drug Targets; 2019; 19(2):133-140. PubMed ID: 30073931
[TBL] [Abstract][Full Text] [Related]
20. Screening for
Chakouri N; Farah C; Matecki S; Amedro P; Vincenti M; Saumet L; Vergely L; Sirvent N; Lacampagne A; Cazorla O
Theranostics; 2020; 10(18):8130-8142. PubMed ID: 32724462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
